Radiation Therapy

Radiation therapy (radiotherapy) uses controlled beams of ionizing radiation to destroy cancer cells while sparing as much healthy tissue as possible. It is one of the three pillars of cancer treatment alongside surgery and systemic therapy, and roughly half of all cancer patients receive radiation at some point in their care — for cure, for symptom control, or as an adjunct to tighten local control after surgery or chemotherapy.

What makes radiotherapy so useful is a quiet biological asymmetry: cancer cells, dividing frequently and often carrying broken DNA-repair machinery, tend to be more vulnerable to radiation-induced damage than the slow-dividing normal tissue around them. The entire discipline is built on exploiting that gap — delivering enough dose to kill the tumor while keeping normal-tissue injury within tolerable limits. This page explains how radiation actually kills cells, why we split the dose into daily "fractions," and how modern machines sculpt the dose to millimeter precision.

Learning Objectives

• Explain how ionizing radiation damages DNA through direct and indirect (free-radical) mechanisms.
• Describe why double-strand breaks are the lethal lesion and how cell death occurs.
• State the "4 Rs" of radiobiology and explain why fractionation improves the therapeutic ratio.
• Distinguish external beam radiotherapy, brachytherapy, and systemic radionuclide therapy.
• Compare modern delivery techniques (3D-CRT, IMRT, VMAT, SBRT, protons) and their rationale.
• Recognize acute versus late radiation toxicity and the concept of normal-tissue tolerance.

Quick Answer

Ionizing radiation kills cancer cells mainly by damaging DNA. About two-thirds of the damage from X-rays is indirect — radiation ionizes water to create hydroxyl free radicals that attack the DNA backbone; the rest is direct ionization of DNA itself. The critical lethal lesion is the double-strand break, which, if unrepaired or misrepaired, causes the cell to die when it next attempts to divide (mitotic catastrophe). Because normal tissues repair sublethal damage better than tumors do, the total dose is split into many small daily fractions (typically 1.8–2 Gy each), which spares normal tissue while still killing tumor. Modern delivery — IMRT, VMAT, SBRT, brachytherapy, and proton therapy — shapes the dose tightly around the target to maximize tumor dose and minimize collateral injury.

Where It Came From

Radiotherapy was born within months of the discovery of the tools themselves — a rare case where a new physics phenomenon jumped almost immediately to the bedside because the human need was so pressing: cancer was largely untreatable, and here was something that visibly shrank tumors.

Wilhelm Roentgen (1895) discovered X-rays while experimenting with a cathode-ray tube in Wurzburg, noticing a fluorescent screen glowing across the room and then imaging the bones of his wife's hand. He called the unknown rays "X." The discovery electrified science and medicine; within weeks physicians worldwide were making radiographs, and by 1896 X-rays were being aimed at tumors and lupus lesions. Roentgen received the first Nobel Prize in Physics in 1901.

Henri Becquerel (1896) discovered natural radioactivity when uranium salts fogged a photographic plate in the dark. Marie and Pierre Curie then isolated polonium and radium (1898), coining the term "radioactivity." Radium's intense, portable radiation made it the workhorse of early therapy: sealed radium sources were placed directly on or inside tumors — the origin of brachytherapy (from Greek brachys, "short"). Marie Curie won two Nobel Prizes (Physics 1903, Chemistry 1911). The era's cost was steep: Marie Curie died of aplastic anemia almost certainly linked to lifelong radiation exposure, and many early "radium girls" and pioneers suffered radiation injury before dosimetry and shielding were understood.

The real conceptual leap came in the 1920s–1930s in France. Claudius Regaud and Henri Coutard at the Institut du Radium showed that dividing radiation into multiple smaller daily doses — fractionation — could sterilize tumors (their model was ram testes and head-and-neck cancers) while avoiding the catastrophic skin and tissue burns caused by a single massive dose. This is the birth of the daily-fraction schedule still used today. The mid-century arrival of cobalt-60 teletherapy (1950s) and then the linear accelerator (linac) delivered high-energy beams that penetrated deep tumors while sparing skin, and CT-based planning from the 1970s onward turned radiotherapy into the image-guided, computer-optimized discipline it is now.

How Ionizing Radiation Kills Cancer Cells

Ionization. "Ionizing" radiation carries enough energy to eject electrons from atoms. In therapy this is delivered as photons (X-rays or gamma rays), electrons, or heavier charged particles (protons, occasionally carbon ions). As radiation traverses tissue it deposits energy along its track, creating ionizations.

Direct vs indirect action. DNA can be hit two ways:

• Direct action: the radiation ionizes the DNA molecule itself. This dominates for high-LET (linear energy transfer) radiation such as alpha particles and carbon ions.
• Indirect action: the radiation ionizes water — the most abundant molecule in the cell — producing reactive species, chiefly the hydroxyl radical (·OH). These free radicals diffuse a few nanometers and chemically attack DNA. For conventional low-LET X-rays, roughly two-thirds of the damage is indirect.

Why oxygen matters (the oxygen effect). When a radical damages DNA in the presence of oxygen, the oxygen "fixes" (makes permanent) the lesion by forming a stable peroxide. In hypoxic (low-oxygen) tissue the damage is more often chemically restored. Well-oxygenated cells are therefore up to ~3 times more radiosensitive than hypoxic ones — quantified as the oxygen enhancement ratio. This is why the hypoxic cores of large tumors are notoriously radioresistant.

The lethal lesion — double-strand breaks. Radiation produces base damage, single-strand breaks (SSBs), and double-strand breaks (DSBs). SSBs and base damage are usually repaired accurately using the intact complementary strand. The DSB — both strands severed close together — is the critical killing lesion: it is hard to repair faithfully and, if misrepaired, produces lethal chromosomal aberrations (dicentrics, rings, acentric fragments).

How the cell actually dies. Most solid-tumor cells die by mitotic catastrophe: the cell carries its damaged chromosomes into the next mitosis, cannot segregate them properly, and dies during or after that division. This is why radiation kills proliferating tissue preferentially and why effects are delayed rather than instantaneous. Some cell types (lymphocytes, salivary acinar cells, spermatogonia) instead die rapidly by apoptosis. At high single doses used in stereotactic treatment, additional mechanisms — endothelial/vascular damage and possibly enhanced immune recognition — contribute.

Cell-survival curves. The dose–response for cell killing follows the linear-quadratic (LQ) model: surviving fraction ≈ exp(−αD − βD²). The α (linear) term reflects lethal single-track events (one particle causing a DSB); the β (quadratic) term reflects damage from two separate tracks that combine. The ratio α/β captures how a tissue responds to dose per fraction — high for tumors and acutely reacting tissues (~10 Gy), low for late-reacting normal tissues like spinal cord (~2–3 Gy). This single number drives fractionation strategy.

Fractionation: Why We Split the Dose

Delivering, say, 60 Gy in one sitting would be lethal to normal tissue. Instead we give it as ~30 daily fractions of 2 Gy. The rationale is captured by the "4 Rs" of radiobiology:

• Repair of sublethal damage — normal (late-reacting) tissue repairs between daily fractions more effectively than tumor, so spreading dose out spares it preferentially.
• Reassortment (redistribution) — cells in resistant phases of the cycle (late S) move into sensitive phases (G2/M) between fractions, so more get caught vulnerable.
• Reoxygenation — as radiosensitive oxygenated cells die and the tumor shrinks, previously hypoxic cells regain oxygen and become sensitive to later fractions.
• Repopulation — surviving tumor cells keep dividing during a course, so treatment should not be prolonged unnecessarily; accelerated repopulation after ~4 weeks is a reason to avoid treatment gaps.

A fifth "R," radiosensitivity (intrinsic differences between tumor types), is often added.

Fractionation schedules.

• Conventional: 1.8–2 Gy/fraction, one fraction per day, 5 days/week.
• Hyperfractionation: smaller doses, twice daily — more total dose to the tumor while sparing late-reacting tissue (exploits the low α/β of normal tissue).
• Hypofractionation: larger doses in fewer fractions (e.g., breast 40 Gy in 15, prostate SBRT). Modern evidence shows this is safe and equally effective for tumors that happen to share a low α/β with normal tissue (prostate, breast), and it is far more convenient.
• Palliative: short courses (e.g., 8 Gy single fraction for bone metastasis) prioritizing quick symptom relief over long-term normal-tissue sparing.

Worked example. A head-and-neck cancer is treated to 70 Gy in 35 fractions of 2 Gy over 7 weeks. Each 2 Gy fraction kills a roughly constant fraction of surviving tumor cells (log-kill), while the normal mucosa and salivary glands are given time to repair overnight. Reoxygenation over the weeks progressively sensitizes the once-hypoxic tumor core. Because head-and-neck tumors repopulate fast, oncologists avoid unplanned breaks and try to finish on schedule — every extra week can cost tumor control.

Modern Delivery: From Broad Beams to Sculpted Dose

External beam radiotherapy (EBRT) using a linear accelerator is the most common form. Progressive refinement:

• 3D conformal radiotherapy (3D-CRT): CT-based planning shapes multiple beams to the tumor outline.
• IMRT (intensity-modulated RT): beam intensity is varied across each field using a multileaf collimator, allowing concave dose distributions that wrap around critical structures (e.g., sparing the parotid or spinal cord).
• VMAT (volumetric modulated arc therapy): the gantry rotates while continuously shaping the beam — fast, highly conformal delivery.
• IGRT (image-guided RT): on-board imaging (cone-beam CT) before each fraction corrects for daily setup and organ motion.
• SBRT/SRS (stereotactic body RT / radiosurgery): very high dose in 1–5 fractions to small, well-defined targets (early lung cancer, brain metastases, oligometastases) with steep dose gradients. SRS to the brain (Gamma Knife, CyberKnife, linac-based) can ablate lesions in a single session.

Particle therapy — protons. Photons deposit dose all along their path, including an exit dose beyond the tumor. Protons deposit most of their energy at a defined depth (the Bragg peak) and then stop, with essentially no exit dose. This spares tissue behind the target and is especially valuable in children (reducing late second cancers) and tumors abutting critical structures (skull base, spinal cord).

Brachytherapy. Radioactive sources are placed within or next to the tumor, giving a very high local dose that falls off steeply with distance (inverse-square law). Cornerstone of cervical cancer treatment (intracavitary), also used in prostate (permanent seed implants or HDR) and some skin and breast cancers.

Systemic radionuclide therapy. Radioisotopes are given as drugs that seek their target: radioactive iodine (I-131) for thyroid cancer, Ra-223 for bone-predominant prostate metastases, and Lu-177-based agents (PSMA for prostate, DOTATATE for neuroendocrine tumors) — a fast-growing "theranostic" field.

Real-World Applications

• Curative: early-stage larynx, prostate, cervix, and non-small-cell lung cancers can be cured by radiation alone; SBRT rivals surgery for inoperable early lung cancer.
• Adjuvant: post-lumpectomy breast irradiation dramatically cuts local recurrence; post-op RT after head-and-neck or high-risk resections mops up microscopic disease.
• Neoadjuvant: chemoradiation before surgery downstages rectal and esophageal cancers.
• Concurrent chemoradiation: cisplatin or other agents act as radiosensitizers in cervix, head-and-neck, anal, and lung cancers.
• Palliative: rapid relief of painful bone metastases, bleeding tumors, brain metastases, and malignant spinal cord compression (an oncologic emergency).
• Benign uses: occasionally for keloids, heterotopic ossification prophylaxis, and some vascular malformations.

Common Mistakes

• Misconception: "Radiation makes you radioactive." Why it's wrong: External beam radiation passes through you and deposits energy; it leaves no residual radioactivity. Patients are safe to be around family. Correction: Only certain internal treatments require temporary precautions — sealed brachytherapy sources while in place, and systemic radionuclides (I-131, Lu-177) for a limited period. EBRT patients need no isolation.

• Misconception: "Radiation kills the tumor immediately." Why it's wrong: Because most cells die at their next mitosis, tumors often shrink over weeks to months, and imaging response lags. Judging failure too early is a mistake. Correction: Assess response on the appropriate timeline and expect delayed regression.

• Misconception: "A bigger single dose is always more effective." Why it's wrong: A single large dose maximizes normal-tissue damage and forfeits the benefits of reoxygenation and normal-tissue repair between fractions. Correction: Fractionation exists precisely to widen the therapeutic window; large single doses are reserved for small, well-defined targets (SRS) where the geometry protects normal tissue.

• Misconception: "Acute side effects predict late damage." Why it's wrong: Acute effects (mucositis, skin reaction) arise in fast-turnover tissues and largely heal; late effects (fibrosis, myelopathy) arise in slow-turnover tissues and are often permanent. They are governed by different biology (different α/β). Correction: Manage them as distinct problems; a mild acute course does not guarantee freedom from late toxicity.

Comparison and Connections

Feature	External beam (EBRT)	Brachytherapy	Systemic radionuclide
Source location	Machine outside body	Inside/next to tumor	Injected/ingested drug
Dose falloff	Shaped by beams	Very steep (inverse square)	Determined by biodistribution
Typical use	Most solid tumors	Cervix, prostate	Thyroid, prostate bone mets, NETs
Radiation safety	None after treatment	Precautions while source in place	Temporary precautions

Acute vs late toxicity: acute effects (days to weeks) hit rapidly dividing tissue — mucosa, skin, marrow, gut — and usually recover; late effects (months to years) — fibrosis, telangiectasia, spinal cord myelopathy, second malignancies — reflect slow-turnover tissue and vascular injury, and are the true dose-limiting factors captured by normal-tissue tolerance doses.

Photons vs protons: photons are cheaper and universally available with an exit dose; protons stop at the Bragg peak, sparing distal tissue — an advantage that matters most in children and near critical organs.

Practice Questions

Recall

Q: What is the critical lethal DNA lesion produced by ionizing radiation? A: The double-strand break (DSB) — hard to repair faithfully, causing lethal chromosomal aberrations and cell death at mitosis.

Understanding

Q: Explain why well-oxygenated tumor cells are more radiosensitive than hypoxic ones. A: For low-LET radiation, most damage is via free radicals. Oxygen "fixes" the radical-induced DNA lesion into a permanent chemical change; without oxygen the lesion is more often chemically repaired. Oxygenated cells can be up to ~3× more sensitive (the oxygen enhancement ratio), which is why hypoxic tumor cores resist radiation.

Application

Q: A prostate cancer (low α/β, ~1.5 Gy) is a candidate for hypofractionation. Why is a larger dose per fraction biologically justified here? A: Tissues with a low α/β are relatively more sensitive to increases in dose per fraction. When the tumor's α/β is as low as (or lower than) the surrounding late-reacting normal tissue, larger fractions preferentially damage the tumor without a disproportionate late-toxicity penalty — so fewer, larger fractions give equal control with more convenience.

Analysis

Q: During a 7-week head-and-neck course a patient misses a week due to illness. Why does this threaten tumor control, and what might a clinician do? A: Surviving tumor cells undergo accelerated repopulation after roughly 4 weeks; a gap lets the tumor regrow, effectively "wasting" some prior dose. Clinicians may compensate by adding fractions, treating twice daily to catch up, or otherwise minimizing total treatment time to preserve the biologically effective dose.

FAQ

Does radiation therapy hurt? The treatment itself is painless — like having an X-ray. Discomfort comes from cumulative side effects in the treated area (sore skin, mucositis, fatigue), which build over weeks and then heal.

How long is a typical course? Highly variable: a single palliative fraction; ~1–5 sessions for SBRT/SRS; 3 weeks for many modern breast schedules; 6–8 weeks for radical head-and-neck or prostate courses. Each daily session takes only minutes on the table.

Will I lose my hair? Only hair in the radiation field. Whole-brain radiation causes scalp hair loss; pelvic radiation does not affect the scalp. Chemotherapy, not radiotherapy, causes generalized hair loss.

Can the same area be treated twice? Sometimes ("re-irradiation"), but normal tissues have a memory of prior dose, so cumulative tolerance limits (especially spinal cord) constrain it. Modern precision techniques have made careful re-treatment more feasible.

Is radiation therapy dangerous to my family? For external beam and after most treatments, no — you are not radioactive. Only temporary precautions apply during sealed-source brachytherapy or after certain radionuclide therapies like I-131, and your team will give clear instructions.

Quick Revision

• Radiation kills cells mainly by DNA damage; ~2/3 of X-ray damage is indirect via hydroxyl free radicals.
• The double-strand break is the lethal lesion; most solid-tumor cells die by mitotic catastrophe at mitosis.
• Oxygen fixes damage — oxygenated cells are up to ~3× more sensitive (oxygen enhancement ratio).
• Cell survival follows the linear-quadratic model; α/β is high for tumors (~10) and low for late-reacting tissue (~2–3).
• Fractionation exploits the 4 Rs: Repair, Reassortment, Reoxygenation, Repopulation.
• Conventional dosing ~1.8–2 Gy/fraction; hypofractionation suits low-α/β tumors (breast, prostate).
• Delivery: 3D-CRT → IMRT → VMAT, with IGRT for accuracy; SBRT/SRS for ablative small targets.
• Protons stop at the Bragg peak (no exit dose); brachytherapy gives steep local dose; radionuclides act systemically.
• History: Roentgen (X-rays, 1895), Becquerel and the Curies (radioactivity/radium), Regaud and Coutard (fractionation, 1920s–30s).
• Acute toxicity (fast-turnover tissue) heals; late toxicity (slow-turnover) is dose-limiting and often permanent.

Related Topics

Prerequisites

• Oncology overview
• Cell cycle and DNA repair (see ../../3._Biochemistry/index.md)

Related Topics

• Chemotherapy and systemic radiosensitizers (see the Oncology branch overview: ../index.md)
• Cancer biology and carcinogenesis (see ../../4._Pathology/index.md)

Next Topics

• Palliative care and symptom control in oncology (../index.md)
• Diagnostic and functional imaging in treatment planning (see ../../1._Anatomy/index.md for cross-sectional anatomy)